Prognostic Factors in Childhood Acute Lymphoblastic Leukemia

Indian Journal of Pediatrics

Volumn 70, Issue 10, 2003, Pages 817-824

  Schrappe, Martin ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Childhood ALL; Leukemia; MRD; Prognostic factors; Treatment response

Indexed keywords

IMMUNOGLOBULIN; T LYMPHOCYTE RECEPTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; CANCER RECURRENCE; CANCER SUSCEPTIBILITY; CHILD; CHILDHOOD CANCER; CONFERENCE PAPER; CYTOGENETICS; FEMALE; GENE REARRANGEMENT; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA CELL; LEUKOCYTE COUNT; MALE; MINIMAL RESIDUAL DISEASE; PROGNOSIS; SENSITIVITY AND SPECIFICITY; TREATMENT INDICATION;

EID: 0242656051     PISSN: 00195456     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02723806     Document Type: Conference Paper

References (44)

1. Reiter A, Schrappe M, Ludwig W-D, Hiddemann W, Sauter S, Henze G et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
2. Schorin MA, Blattner S, Gelber RD, Tarbell NJ, Donnelly M, Dalton V et al. Treatment of childhood acute lymphoblastic leukemia: Results of Dana-Farber Cancer Institute/Children's Hospital Acute Lymphoblastic Leukemia Consortium Protocol 85-01. J Clin Oncol 1994; 12: 740-747.
3. Chessells JM, Bailey C, Richards SM. Intensification of treatment and survival in all children with lymphoblastic leukaemia: results of UK Medical Research Council trial UKALL X. Lancet 1995; 345: 143-148.
4. Pui CH. Childhood leukemias. N Engl J Med 1995; 332: 1618-1630.
5. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 1998; 338: 1663-1671.
6. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G et al, Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000; 14: 2205-2222.
7. Riehm H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D et al. Results and significance of six randomized trials in four consecutive ALL-BFM trials. Haematol Blood Transfus 1990; 33: 439-450.
8. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ et al. Improved outcome with delayed intensification for children with acute lymphoblastic leukemia and intermediate presenting features: a Childrens Cancer Group phase III trial. J Clin Oncol. 1993; 11: 527-537.
9. Schrappe M, Reiter A, Riehm H. Prophylaxis and treatment of meningeosis in childhood acute lymphoblastic leukemia. J Neuro-Oncol 1998; 38: 159-165.
10. Riehm H, Reiter A, Schrappe M, Berthold F, Dopfer R, Gerein H et al. Die Corticosteroid-abhängige Dezimierung der Leukämiezellzahl im Blut als Prognosefaktor bei der akuten lymphoblastischen Leukämie im Kindesalter (Therapiestudie ALL-BFM 83) [The in vivo response on corticosteroid therapy as an additional prognostic factor in childhood acute lymphoblastic leukemia (therapy study ALL-BFM 83). Klin Pädiatr 1987; 199: 151-160.
11. Schrappe M, Reiter A, Ludwig W-D, Harbott J, Zimmermann M, Hiddemann W et al. Improved outcome in childhood ALL despite reduced use of anthracyclines and of cranial radiotherapy: Results of trial ALL-BFM 90. Blood 2000; 95: 3310-3322.
12. Gajjar A, Ribeiro R, Hancock ML, Rivera GK, Mahmoud H, Sandlund JT et al. Persistence of circulating blasts after 1 week of multiagent chemotherapy confers a poor prognosis in childhood acute lymphoblastic leukemia. Blood 1995; 86: 1292-1295.
13. Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH et al. Cytoreduction and prognosis in acute lymphoblastic leukemia - the importance of early marrow response: report from the Childrens Cancer Group. J Clin Oncol 1996; 14: 389-398.
14. Gaynon PS, Desai AA, Bostrom BC, Hutchinson RJ, Lange BJ, Nachman JB et al. Early response to therapy and outcome in childhood acute lymphoblastic leukemia: a review. Cancer 1997; 80: 1717-1726.
15. Coustan-Smith E, Behm FG, Sanchez J, Boyett JM, Hancock ML, Raimondi SC et al. Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia. Lancet 1998; 351: 550-554.
16. Van Dongen JJM, Seriu T, Panzer-Grumayer ER, Biondi A, Pongers-Willemse MJ, Corral L et al. Prognostic value of minimal residual disease in childhood acute lymphoblastic leukemia: A prospective study of the International BFM Study Group. Lancet 1998; 352: 1731-1738.
17. Biondi A, Valsecchi MG, Seriu T, d'Aniello E, Willemse MJ, Fasching K et al. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group. Leukemia 2000; 14: 1939-1943.
18. Panzer-Grumayer ER, Schneider M, Panzer S, Fasching K, Gadner H. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia. Blood 2000; 95: 790-794.
19. Zur Stadt U, Harms DO, Schluter S, Schrappe M, Goebel U, Spaar H et al. MRD at the end of induction therapy in childhood acute lymphoblastic leukemia: outcome prediction strongly depends on the therapeutic regimen. Leukemia 2001; 15:283-285.
20. Nyvold C, Madsen HO, Ryder LP, Seyfarth J, Svejgaard A, Clausen N et al. Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome. Blood 2002; 99: 1253-1258.
21. Smith M, Arthur D, Camitta B, Carroll AJ, Crist W, Gaynon P et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24.
22. Schlieben S, Borkhardt A, Reinisch I, Ritterbach J, Janssen JWG, Ratei R et al. Incidence and clinical outcome of children with BCR/ABL-positive acute lymphoblastic leukemia (ALL). A prospective RT-PCR study based on 673 patients enrolled in the German pediatric multicenter therapy trials ALL-BFM 90 and CoALL-05-92. Leukemia 1996; 10: 957-963.
23. Schrappe M, Reiter A, Harbott J, Zimmermann M, Henze G, Boos J et al. Improved Risk-Adapted Treatment of Childhood ALL with a New Stratification System Based on Early Response, Genetics, Age, and WBC: First Interim Analysis of Trial ALL-BFM 95. Blood 2001; 98: 718a
24. Aricò, M, Valsecchi MG, Conter V, Rizzari C, Pession A, Messina C et al. Improved outcome in high risk childhood acute lymphoblastic leukemia defined by prednisone poor response treated with double BFM Protocol II. Blood 2002; 100: 420-426.
25. Foroni L, Coyle LA, Papaioannou M, Yaxley JC, Sinclair MF, Chim JS et al. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response. Leukemia 1997; 11: 1732-1741.
26. Seriu T, Erz D, Stark Y, Bartram CR. T cell receptor Ddelta2Ddelta3 rearrangement: a suitable allele-specific marker for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 1997; 11: 759-761.
27. Willemse MJ, Seriu T, Hettinger K, d'Aniello E, Hop WC, Panzer-Grumayer ER et al. Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL. Blood 2002; 99 (12): 4386-4393.
28. Cave H, van der Werff ten Bosch J, Suciu S, Guidal C, Waterkeyn C, Otten J et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer - Childhood Leukemia Cooperative Group. N Engl J Med 1998; 339 (9): 591-598.
29. Dworzak MN, Froschl G, Printz D, Mann G, Potschger U, Muhlegger N et al. Prognostic significance and modalities of flow cytometric minimal residual disease detect ion in childhood acute lymphoblastic leukemia. Blood 2002; 99 (6): 1952-1958.
30. Gaynon PS, Steinherz PG, Bleyer WA, Ablin AR, Albo VC, Finklestein JZ et al. Improved therapy for children with acute lymphoblastic leukemia and unfavorable presenting features: a follow-up report of the Childrens Cancer Group Study CCG-106. J Clin Oncol 1993; 11: 2234-2242.
31. Riehm H, Gadner H, Henze G, Langermann H-J, Odenwald E. The Berlin childhood acute lymphoblastic leukemia therapy study, 1970-1976. Am J Pediatr Hematol Oncol 1980; 2: 299-306.
32. Reiter A, Schrappe M, Ludwig WD, Tiemann M, Parwaresch R, Zimmermann M et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000; 95: 416-421.
33. Schrappe M, Arico M, Harbott J, Biondi A, Zimmermann M, Conter V et al. Ph+ childhood acute lymphoblastic leukemia: good initial steroid response allows early prediction of a favorable treatment outcome. Blood 1998; 92: 2730-2741.
34. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A et al. Outcome of treatment in children with Philadelphia chromosome- positive acute lymphoblastic leukemia. N Engl J Med 2000; 342 (14): 998-1006.
35. Pui CH, Gaynon PS, Boyett JM, Chessells JM, Baruchel A, Kamps W et al. Outcome of treatment in childhood acute lymphoblastic leukaemia with rearrangements of the 11q23 chromosomal region. Lancet 2002; 359 (9321): 1909-1915.
36. Bührer C, Hartmann R, Fengler R, Rath B, Schrappe M, Janka-Schaub G et al. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. J Clin Oncol 1996; 14: 2812-2817.
37. Eckert C, Biondi A, Seeger K, Cazzaniga G, Hartmann R, Beyermann B et al. Prognostic value of minimal, residual disease in relapsed childhood acute lymphoblastic leukaemia. Lancet 2001; 358:1239-1241.
38. Chessells JM, Richards SM, Bailey CC, Lilleyman JS, Eden OB. Gender and treatment outcome in childhood lymphoblastic leukaemia: report from the MRC UKALL trials. Br J Haematol 1995; 89: 364-372.
39. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman P et al. Day 7 marrow response and outcome for children with acute lymphoblastic leukemia and unfavorable presenting features. Med Pediatr Oncol 1990; 18: 273-279.
40. Doerdelmann M, Reiter A, Borkhardt A, Ludwig W-D, Götz N, Viehmann S et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217.
41. Reiter A, Schrappe M, Ludwig WD, Lampert F, Harbott J, Henze G et al. Favorable outcome of B-cell acute lymphoblastic leukemia in childhood: a report of three consecutive studies of the BFM group. Blood 1992; 80: 2471-2478.
42. Reiter A, Schrappe M, Tiemann M, Ludwig WD, Yakisan E, Zimmermann M et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999; 94: 3294-3306.
43. Sallan SE, Gelber RD, Kimball V, Donnelly M, Cohen HJ. More is better! Update of Dana-Farber Cancer Institute/Children's Hospital childhood acute lymphoblastic leukemia trials. Haematol Blood Transfus 1990; 33: 459-466.
44. Rivera GK, Raimondi SC, Hancock ML, Behm FG, Pui CH, Abromowitch M et al. Improved outcome in childhood acute lymphoblastic leukaemia with reinforced early treatment and rotational combination chemotherapy. Lancet 1991; 337: 61-66.